Synapse - Works

Results (116624)

Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma

Meeting Abstract

Gounder, M. M.; Merriam, P.; Ratan, R.; Patel, S. R.; Chugh, R.; Villalobos, V.; Thorton, M.; Van Tine, B. A.; Abdelhamid, A. H.; Joshi, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option

Meeting Abstract

Liu, S. V.; Duruisseaux, M.; Tolba, K.; Branden, E.; Goto, Y.; Weinberg, B. A.; Renouf, D. J.; Doebele, R. C.; Heining, C.; Schlenk, R. F.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

Meeting Abstract

Tolaney, S. M.; Wardley, A. M.; Zambelli, S.; Hilton, J.; Troso-Sandoval, T.; Ricci, F.; Im, S. A.; Kim, S. B.; Johnston, S. R. D.; Chan, A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings

Meeting Abstract

Kristeleit, R. S.; Oza, A. M.; Oaknin, A.; Aghajanian, C.; Tinker, A. V.; Tredan, O.; O'Malley, D. M.; Leary, A.; Konecny, G. E.; Lorusso, D.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M. H.; Shaffer, D.; Hsieh, J. J.; Cohn, A. L.; DiSimone, C.; Pinto Marin, A.; Rasco, D. W.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data

Meeting Abstract

D'Angelo, S. P.; Nolte, S.; Schlichting, M.; Henry-Szatkowski, M.; Hennessy, M.; Bharmal, M.
Annals of Oncology (2019)

Fulltext@MSK | Save

Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Meeting Abstract

De Braud, F. G. M.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B. P.; Huang, X.; Ye, C.; Doebele, R. C.
Annals of Oncology (2019)

Fulltext@MSK | Save

Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study

Meeting Abstract

Reckamp, K. L.; Akerley, W.; Calvo, E.; Clarke, J.; Edelman, M. J.; He, K.; Moreno, V.; Neal, J. W.; Owonikoko, T. K.; Patel, J. D.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

Meeting Abstract

Necchi, A.; Fradet, Y.; Bellmunt, J.; de Wit, R.; Lee, J. L.; Fong, L.; Vozelgang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Meeting Abstract

Hoffman-Censits, J.; Rosenberg, J. E.; van Der Heijden, M.; Dreicer, R.; Perez Gracia, J. L.; Petrylak, D. P.; Retz, M. M.; Sabbatini, R.; Naglieri, E.; Caserta, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save